Company Profile

Avantyx Pharmaceuticals LLC
Profile last edited on: 3/18/22      CAGE: 8JZA3      UEI: CVYRLJ3H5DL7

Business Identifier: Addressing chemotherapy-induced peripheral neuropathy
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1951 NW 7th Street
Miami, FL 33136
   (305) 302-1284
Location: Single
Congr. District: 27
County: Miami-Dade

Public Profile

Avantyx is structured around prevention and cure of Peripheral Neuropathy (CIPN) - a nerve-damaging side effect of antineoplastic agents used in cancer treatment. Recent data suggest that some 70% of patients undergoing chemotherapy will develop the condition. The condition is defined as causing pain, tingling, temperature sensitivity, and numbness in the hands and feet. With Avantyx founders having studied the root cause of peripheral neuropathy for many years, what may be a breakthrough discovery - identification of a unique mechanism that causes peripheral - may have been made. Based on those finding, the team is working on a compound (potentially) not only could cure - but will also prevent the condition from occurring in the first place .. improving patient survival rates and quality of life for all those involved.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $355,723
Project Title: Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN

Key People / Management

  Sandra Rieger -- Founder and CEO

  Bianca Ruiz -- Co-Founder & COO

Company News

There are no news available.